Abstract
Introduction
A decrease of insulin-like growth factor-I levels (IGF-I) has been reported during the first trimester of pregnancy in women with acromegaly before the secretion of placental growth hormone (GH) progressively increases IGF-1 concentration.
Study design
To evaluate variations of concentrations of IGF-1, insulin-like growth factor (IGF)-binding protein-3 (IGF-BP3) and GH during the first trimester of pregnancy in women with normal somatotroph function.
Patients and methods
Sixteen women (median age 31 years) with as who were followed for benign thyroid disorders (n = 15) or prolactin-secreting microadenoma (n = 1) were evaluated before and in the first trimester of pregnancy. Serum concentrations of GH, IGF-1, IGF-BP3, TSH and estradiol (E2) were measured before and in the first trimester (5.4 ± 2.2 weeks of gestation).
Results
Before pregnancy, somatotroph and thyroid functions (median TSH 1.2 mU/L) were normal in all women. At the first trimester IGF-1 levels decreased significantly (before = 210 ng/mL, first trimester = 145 ng/mL, p < 0.001) with no significant change in GH (before = 1.5 ng/mL, first trimester = 0.84 ng/mL) or IGF-BP3 levels (before = 2.3 ng/mL, first trimester = 2.2 ng/mL), while estradiol levels increased significantly (before = 46.5 pg/100 mL, first trimester = 448.5 pg/100 mL, p < 0.001).
Conclusion
In women with normal somatotroph function, IGF-1 levels decrease in the first trimester of pregnancy without changes in GH or IGF-BP3 levels. These results confirm liver resistance to GH as a consequence of the physiological increase of estrogens during the first trimester.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melled S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141–3148
Span JP, Pieters GF, Sweep CG, Hermus AR, Smals AG (2000) Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. J Clin Endocrinol Metab 85:1121–1125
Van der Klaauw AA, Biermasz NR, Zelissen PM, Pereira AM, Lentjes EG, Smit JW, van Thiel SW, Romijn JA, Roelfsema F (2007) Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism. Eur J Endocrinol 157:709–716
Isotton AL, Wender MC, Casagrande A, Rollin G, Czepielewski MA (2012) Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study. Eur J Endocrinol 166:207–213
Leung KC, Johannsson G, Leong GM, Ho KK (2004) Estrogen regulation of growth hormone action. Endocr Rev 25:693–721
Ovesen P, Vahl N, Fisker S, Veldhuis JD, Christiansen JS, Jørgensen JO (1998) Increased pulsatile, but not basal, growth hormone secretion rates and plasma insulin-like growth factor I levels during the periovulatory interval in normal women. J Clin Endocrinol Metab 83:1662–1667
Hudson SB, Schroeder DR, Bailey JN, Mielke KL, Erickson D, Miles JM, Bowers CY, Veldhuis JD (2010) Pre- versus postmenopausal age, estradiol, and peptide-secretagogue type determine pulsatile growth hormone secretion in healthy women: studies using submaximal agonist drive and an estrogen clamp. J Clin Endocrinol Metab 95:353–360
Veldhuis JD, Hudson SB, Erickson D, Bailey JN, Reynolds GA, Bowers CY (2009) Relative effects of estrogen, age, and visceral fat on pulsatile growth hormone secretion in healthy women. Am J Physiol Endocrinol Metab 297:E367–E374
Parkinson C, Ryder WD, Trainer PJ (2001) Sensus Acromegaly Study Group. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab 86:5240–5244
Caufriez A, Frankenne F, Hennen G, Copinschi G (1993) Regulation of maternal IGF-I by placental GH in normal and abnormal human pregnancies. Am J Physiol 265:E572–E577
Colao A, Merola B, Ferone D, Lombardi G (1997) Acromegaly. J Clin Endocrinol Metab 82:2777–2781
Cozzi R, Attanasio R, Barausse M (2006) Pregnancy in acromegaly: a one-center experience. Eur J Endocrinol 155:279–284
Lau SL, McGrath S, Evain-Brion D, Smith R (2008) Clinical and biochemical improvement in acromegaly during pregnancy. J Endocrinol Invest 31:255–261
Caron P, Broussaud S, Bertherat J, Borson-Chazot F, Brue T, Cortet-Rudelli C, Chanson P (2010) Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. J Clin Endocrinol Metab 95:4680–4687
Persechini ML, Gennero I, Grünenwald S, Vezzosi D, Bennet A, Caron P (2013) Acromégalie et grossesse: six nouvelles observations. J Gynecol Obstet Biol Reprod (Paris), doi:10.1016/j.jgyn.2013.04.008
Clapp JF 3rd, Schmidt S, Paranjape A, Lopez B (2004) Maternal insulin-like growth factor-I levels (IGF-I) reflect placental mass and neonatal fat mass. Am J Obstet Gynecol 190:730–736
Herman-Bonert V, Seliverstov M, Melmed S (1998) Pregnancy in acromegaly: successful therapeutic outcome. J Clin Endocrinol Metab 83:727–731
Beckers A, Stevenaert A, Foidart JM, Hennen G, Frankenne F (1990) Placental and pituitary growth hormone secretion during pregnancy in acromegalic women. J Clin Endocrinol Metab 71:725–731
Wilson DM, Bennett A, Adamson GD, Nagashima RJ, Liu F, DeNatale ML, Hintz RL, Rosenfeld RG (1982) Somatomedins in pregnancy: a cross-sectional study of insulin-like growth factors I and II and somatomedin peptide content in normal human pregnancies. J Clin Endocrinol Metab 55:858–861
Evain-Brion D, Malassine A (2003) Human placenta as an endocrine organ. Growth Horm IGF-1 Res 13 Suppl A: S34–37
Karaca Z, Tanriverdi F, Unluhizarci K, Kelestimur F (2010) Pregnancy and pituitary disorders. Eur J Endocrinol 162:453–475
Lacroix MC, Guibourdenche J, Frendo JL, Muller F, Evain-Brion D (2002) Human placental growth hormone: a review. Placenta 23 Suppl A:S87–94
Kam GY, Leung KC, Baxter RC, Ho KK (2000) Estrogens exert route-and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab 85:1918–1922
Helle SI, Omsjø IH, Hughes SC, Botta L, Hüls G, Holly JM, Lønning PE (1996) Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol 45:727–732
Sonnet E, Lacut K, Roudaut N, Mottier D, Kerlan V, Oger E (2007) Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study. Clin Endocrinol 66:626–631
Le Bouc Y (2007) IGF (insulin-like growth factors). In: Chanson P, Young J. Traité d’endocrinologie, pp 57–61. Editions Flammarion Médecine-Sciences, Paris
Giudice LC, Farrell EM, Pham H, Lamson G, Rosenfeld RG (1990) Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity. J Clin Endocrinol Metab 71:806–816
Wiesli P, Zwimpfer C, Zapf J, Schmid C (2006) Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess. Acta Obstet Gynecol Scand 85:900–905
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Persechini, ML., Gennero, I., Grunenwald, S. et al. Decreased IGF-1 concentration during the first trimester of pregnancy in women with normal somatotroph function. Pituitary 18, 461–464 (2015). https://doi.org/10.1007/s11102-014-0596-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-014-0596-3